Selectively targeting the catalytic center encoded by CHEK1 mRNA and circCHEK1_246aa could effectively target MM cell growth, bone lesion formation, and pathologic changes in the BM niche such as osteoclast differentiation. This evidence concerns the gene CHEK1 and Miyoshi myopathy.